22 reports

  • CLINICAL TRIAL PROFILE SNAPSHOTS

## ## ## ## ## United Kingdom ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## France Source: GlobalData' s Pharma Intelligence Center Clinical

  • Blood Disease
  • Clinical Trial
  • Therapy
  • World
  • Product Initiative

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Angina
  • Blood Disease
  • Cardiovascular Disease
  • Clinical Trial
  • World

## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## ## United Kingdom Source: Glob

  • Acute Coronary Syndrome
  • Blood Disease
  • Cardiovascular Disease
  • Clinical Trial
  • AstraZeneca PLC

We can now start looking at effective drug treatment for other disorders, including autism. "

  • Blood Disease
  • Therapy
  • United States
  • World
  • Product Initiative

Its products are indicated for the treatment of diseases such as Alzheimer' s disease, depression, Parkinson' s disease, schizophrenia, alcohol dependence, anxiety, bipolar I disorder, epilepsy and Huntington' s disease, among others.

  • Blood Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Shire plc
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Blood Disease
  • Clinical Trial
  • Monoclonal Antibody
  • Therapy
  • Novartis AG

It is also evaluating preclinical product candidates for treatment of alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders.

  • Blood Disease
  • United States
  • Company
  • Product Initiative
  • Esperion Therapeutics, Inc.

MENTAL HEALTH CONDITIONS, SUCH AS DEPRESSION, ANXIETY AND STRESS, ARE THE LEADING CAUSE OF DISABILITY WORLDWIDE##.

  • Blood Disease
  • Drug Development
  • Health Services
  • United States
  • Company

The prominent features of this report are - ##.

  • Blood Disease
  • Cardiovascular Disease
  • Clinical Trial
  • Pharmaceutical
  • World
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Anti-Infective
  • Blood Disease
  • Clinical Trial
  • Pharmaceutical
  • World
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Blood Disease
  • Clinical Trial
  • Drug Development
  • Therapy
  • World
  • Eisai Co., Ltd. - Pipeline by Indication, 2016

Research and Development Brief Discovery/ Preclinical Trial Details Product Description Small Molecule to Antagonize CRF-## Receptor for Anxiety Disorders Small molecule is under development for the treatment of anxiety disorder.

  • Blood Disease
  • Cancer
  • Research And Development
  • Therapy
  • Eisai Co., Ltd.

Its preclinical product candidates are intended for treatment of bleeding disorders, alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders.

  • Blood Disease
  • Cardiovascular Disease
  • Chronic Disease
  • Therapy
  • Esperion Therapeutics, Inc.
  • 5. All the trials included are unique trials.

A Double Blind, Randomized, Placebo Controlled Trial Maternal Hypotension During Elective Caesarean Delivery under Various Spinal Anaesthesia Regimens GDCT## ACTRN##, Cardiovascular Arrhythmias, Emesis (Vomiting), Hypotension, Nausea, Unspecified Respiratory Disorders Ongo

  • Blood Disease
  • Clinical Trial
  • Pharmaceutical
  • World
  • Product Initiative

The imbalances in protein acetylation levels and dysfunctions in transcription leads to brain disorders.

  • Blood Disease
  • Hepatitis
  • Therapy
  • United States
  • Product Initiative

With poor eating habits, sedentary lifestyles, stress and anxiety related disorders, drugs and alcoholism contribute to several serious conditions.

  • Blood Disease
  • World
  • Market Size
  • Cyclopharm Limited
  • Lifesciences Limited
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Blood Disease
  • Clinical Trial
  • World
  • Product Initiative
  • Novartis AG
  • LUNG CANCER, OVARIAN CANCER, PERITONEAL TUMOR, RECURRENT GLIOBLASTOMA MULTIFORME (GBM)

Cymbalta is used for the treatment of major depressive disorder, generalized anxiety disorder, pain due to diabetic peripheral neuropathy, fibromyalgia and chronic musculoskeletal pain.

  • Blood Disease
  • Research And Development
  • United States
  • Company Operations
  • Eli Lilly & Co.
  • PRO-131921
  • LEUKEMIA, RELAPSED ACUTE MYELOID LEUKEMIA

As of 2007, it was in Phase I stage of development for the treatment of anxiety disorders.

  • Blood Disease
  • Cancer
  • Monoclonal Antibody
  • Therapy
  • United States

The drug candidate binds to PD-L## and prevents the activation of the PD-## receptor thereby enhancing the T-cell mediated immune response towards immunological disorders.

  • Blood Disease
  • Research And Development
  • Therapy
  • United States
  • Bristol-Myers Squibb Company

The drug candidate was under development for the treatment of bipolar disorder (manic depression) and general anxiety disorder.

  • Blood Disease
  • Cancer
  • Targeted Therapy
  • Therapy
  • Novartis AG

AZD## was under development for the treatment of anxiety disorders.

  • Blood Disease
  • Cancer
  • Therapy
  • United States
  • AstraZeneca PLC